Does MannKind Have the Wrong Strategy?
Biotech company MannKind remains among the most hotly debated speculative plays on the stock market. Its ultra-rapid inhalable insulin drug Afrezza has yet to gain FDA approval, and it will have to compete with Eli Lilly's Humalog, Novo Nordisk's NovoLog, and Sanofi's Apidra if it does eventually get the green light. While MannKind's story continues to unfold, investors might be questioning whether management has made the right moves and pursued the right strategy up to now. Should the company have invested so much into Afrezza, or should the focus have been on licensing its inhaler technology to other companies? Should MannKind have been conceived as a biotech, or as a medical-device maker? Health-care analyst Max Macaluso weighs in on the debate in the following video.
The future of MannKind?
Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more click here to grab your copy today.
The article Does MannKind Have the Wrong Strategy? originally appeared on Fool.com.Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.